Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Phase 1/2 Completed 52 enrolled Groupe Francophone des Myelodysplasies Merck Sharp & Dohme LLC · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated duration and schedule of oral VORINOSTAT in addition to low dose cytarabine in the treatment of Intermediate-2 and High risk myelodysplastic syndromes.

Timeline

Start: 2008-05
Primary completion: 2011-11
Completion: 2011-11

Publications

Prebet T, Braun T, Beyne-Rauzy O, Dreyfus F, Stammatoullas A, Wattel E, Ame S, Raffoux E, Delaunay J, Charbonnier A, Ades L, Fenaux P, Vey N. Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. Leuk Res. 2014 Jan;38(1):29-33. doi: 10.1016/j.leukres.2013.07.023. Epub 2013 Aug 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vorinostat	Small molecule	400 mg	Oral

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Summary

Timeline

Publications

Drugs

Indications